U.S., Oct. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07854509) titled 'A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI Failure' on Sept. 28.
Brief Summary: This is an open-label, multicenter, Phase II clinical study to evaluate the safety, tolerability, and efficacy of SKB264 in combination with SKB118 in participants with locally advanced or metastatic non-squamous NSCLC harboring EGFR-sensitizing mutations who have failed EGFR-TKI therapy. The study includes a dose escalation phase and an expansion phase.
Study Start Date: Oct. 15
Study Type: INTERVENTIONAL
Condition:
Non-Squamous Non-Small Cell Lung Cancer
Intervention:
DRUG: SKB264+SKB118
Administered by intravenous infusion o...